000952.SHE Hubei Guangji Pharmaceutical Co Ltd
- Market cap
- CNY 1.95B
- P/E
- -
- P/B
- 3.21x
- ROE
- -13.4%
- Dividend yield
- 2.61%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 000952.SHE undervalued?
Graham numberThe Graham number of Hubei Guangji Pharmaceutical Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hubei Guangji Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Hubei Guangji Pharmaceutical Co Ltd yet.
Hubei Guangji Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hubei Guangji Pharmaceutical Co Ltd
Hubei Guangji Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical raw materials, pharmaceutical preparations, and feed additives in China and internationally. The company also exports its products. Hubei Guangji Pharmaceutical Co., Ltd. was founded in 1969 and is based in Wuxue, China.
Full company profileHubei Guangji Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hubei Guangji Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 715M | 802M | 844M | 731M | 688M | 786M | 798M | 738M | 639M | 624M | 581M |
| Gross Profit | 372M | 404M | 479M | 335M | 274M | 298M | 287M | 188M | 114M | 166M | 158M |
| Operating Income | 157M | 135M | 211M | 98.9M | 96.8M | 118M | 60.8M | -141M | -318M | -112M | -66.4M |
| EBITDA | 265M | 238M | 322M | 216M | 211M | 232M | 179M | 27.2M | -93.7M | -232M | -41.7M |
| Net Income | 142M | 105M | 172M | 86.9M | 74.6M | 110M | 50.3M | -140M | -295M | -404M | -79.9M |
| EPS | 0.47 | 0.35 | 0.57 | 0.28 | 0.22 | 0.32 | 0.14 | -0.40 | -0.84 | -1.17 | -0.23 |
| Balance Sheet | |||||||||||
| Total Assets | 1.63B | 1.64B | 1.69B | 1.77B | 1.98B | 2.05B | 2.47B | 3.03B | 2.79B | 2.31B | 2.08B |
| Total Liabilities | 975M | 877M | 812M | 802M | 614M | 598M | 977M | 1.64B | 1.72B | 1.69B | 1.51B |
| Shareholders' Equity | 654M | 759M | 873M | 960M | 1.37B | 1.46B | 1.50B | 1.36B | 1.06B | 654M | 597M |
| Cash & Short-term Investments | 117M | 141M | 174M | 184M | 350M | 293M | 431M | 415M | 307M | 278M | 255M |
| Total Debt | 507M | 531M | 552M | 597M | 304M | 373M | 605M | 711M | 739M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 167M | 179M | 231M | 144M | 119M | 75.9M | 45.1M | -149M | 655K | 60.4M | - |
| Capital Expenditure | 113M | 80.9M | 76.5M | 120M | 97.9M | 96.6M | 204M | 566M | 155M | 35.6M | 9.32M |
| Free Cash Flow | 54.1M | 97.9M | 155M | 24.4M | 21.5M | -20.7M | -159M | -715M | -154M | 24.8M | 142M |
| Ratios | |||||||||||
| ROE | 21.7% | 13.9% | 19.7% | 9.1% | 5.4% | 7.5% | 3.3% | -10.3% | -27.7% | -61.9% | -13.4% |
| ROA | 8.7% | 6.4% | 10.1% | 4.9% | 3.8% | 5.4% | 2.0% | -4.6% | -10.6% | -17.5% | -3.8% |
| Net Profit Margin | 19.8% | 13.1% | 20.4% | 11.9% | 10.8% | 14.0% | 6.3% | -19.0% | -46.2% | -64.8% | -13.8% |
| Debt to Equity | 0.78x | 0.70x | 0.63x | 0.62x | 0.22x | 0.25x | 0.40x | 0.52x | 0.69x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Hubei Guangji Pharmaceutical Co Ltd dividends
- Dividend yield
- 2.61%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- May 27, 2022
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 50.9M | 0.15 | - |
| 2024 | CNY 50.5M | 0.14 | - |
| 2023 | CNY 31.6M | 0.09 | - |
| 2022 | CNY 21.2M | 0.06 | 42.0% |
| 2021 | CNY 20.6M | 0.06 | 18.7% |
| 2020 | CNY 77.4M | 0.23 | 103.7% |
| 2019 | CNY 29.3M | 0.10 | 33.7% |
| 2018 | CNY 50.9M | 0.17 | 29.7% |
| 2017 | CNY 31.8M | 0.11 | 30.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.2:1 on May 29, 2020.
Who owns Hubei Guangji Pharmaceutical Co Ltd
- Insiders 32.85%
- Institutions 2.48%
- Public & others 64.67%
- Shares outstanding 344M
- Free float 238M
Hubei Guangji Pharmaceutical Co Ltd company profile
- Company name
- Hubei Guangji Pharmaceutical Co Ltd
- Ticker
- 000952.SHE
- ISIN
- CNE0000010R5
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Aug 20, 1999
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,164
- Fiscal year end
- December
- Address
- No. 100, Meiwu Road, Wuxue, China, 435400
- Phone
- 86 71 7157 5571
- Website
- guangjipharm.com
About Hubei Guangji Pharmaceutical Co Ltd
Hubei Guangji Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical raw materials, pharmaceutical preparations, and feed additives in China and internationally. The company also exports its products. Hubei Guangji Pharmaceutical Co., Ltd. was founded in 1969 and is based in Wuxue, China.
Hubei Guangji Pharmaceutical Co Ltd management
6- Mr. Cheng GongGM & Director · born 1987
- Mr. Yi XiongChief Financial Officer · born 1976
- Mr. Shao Zhi GuoDeputy GM & Director · born 1969
- Mr. Zhi FangDeputy GM & Employee Director · born 1982
- Mr. Yanhua ZhaoDeputy General Manager · born 1987
- Xiaojuan LiuAccounting Supervisor